Bonus Biogroup Debt 2024

Bonus Biogroup Aktienanalyse

What does Bonus Biogroup do?

The Bonus Biogroup Ltd is a biotechnology company based in Israel that specializes in the development and marketing of innovative medical products and therapies based on human bone marrow stem cells. The company was founded in 2008 by a group of scientists, doctors, and entrepreneurs who came together to explore and develop new approaches in regenerative medicine. The business model of Bonus Biogroup is based on utilizing the benefits of stem cells for tissue and organ regeneration. Mesenchymal stem cells (MSC), derived from bone marrow, play an important role in this process. These stem cells have the ability to differentiate into various cell types and have anti-inflammatory properties. Bonus Biogroup aims to utilize MSC technology for the development of innovative medical products and therapies to help patients with serious diseases. The company is divided into several business areas, each offering its own products and services. A key area is the development of implants and other medical devices coated with bone marrow stem cells. These products are intended to promote tissue regeneration in the body, particularly in the treatment of bone and cartilage defects and joint diseases. An example is the BioGrip implant, used in patients with osteoporosis to prevent or reduce bone fractures. Another business area of Bonus Biogroup is the production and marketing of cell therapies. In this process, mesenchymal stem cells are obtained from the patient's bone marrow and processed in a special procedure. The stem cells are then directly injected into the affected area to promote tissue regeneration. These cell therapies are used in patients with rheumatism, arthritis, joint pain, or spinal problems. In addition to research and development of new products and therapies, Bonus Biogroup also operates a large stem cell bank. This bank collects and stores human bone marrow from donors for later use in the production of implants and cell therapies. The stem cell bank is a crucial part of the business model, as it ensures a consistent and high-quality supply of mesenchymal stem cells. In summary, Bonus Biogroup is an innovative biotechnology company specializing in the use of human bone marrow stem cells. The business model is based on the development and marketing of implants, cell therapies, and other medical devices to promote tissue regeneration in the body. The company also operates a large stem cell bank to ensure a consistent supply of high-quality mesenchymal stem cells. The company has the potential to become a significant player in regenerative medicine, making a valuable contribution to improving the health and quality of life of patients. Bonus Biogroup ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Bonus Biogroup's Debt Structure

Bonus Biogroup's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Bonus Biogroup's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Bonus Biogroup’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Bonus Biogroup’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Bonus Biogroup stock

What is the debt of Bonus Biogroup this year?

Bonus Biogroup has a debt level of -41.67 ILS this year.

What was the debt of Bonus Biogroup compared to the previous year?

The debt of Bonus Biogroup has increased by -37.99% compared to the previous year dropped.

What are the consequences of high debt for investors in Bonus Biogroup?

High debt can pose a risk for investors of Bonus Biogroup, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Bonus Biogroup?

Low debt means that Bonus Biogroup has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Bonus Biogroup affect the company?

An increase in debt of Bonus Biogroup can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Bonus Biogroup affect the company?

A reduction in debt of Bonus Biogroup can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Bonus Biogroup?

Some factors that can influence the debt of Bonus Biogroup include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Bonus Biogroup so important for investors?

The debts of Bonus Biogroup are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Bonus Biogroup take to change the debt?

To change the debt, Bonus Biogroup can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Bonus Biogroup pay?

Over the past 12 months, Bonus Biogroup paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Bonus Biogroup is expected to pay a dividend of 0 ILS.

What is the dividend yield of Bonus Biogroup?

The current dividend yield of Bonus Biogroup is .

When does Bonus Biogroup pay dividends?

Bonus Biogroup pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Bonus Biogroup?

Bonus Biogroup paid dividends every year for the past 0 years.

What is the dividend of Bonus Biogroup?

For the upcoming 12 months, dividends amounting to 0 ILS are expected. This corresponds to a dividend yield of 0 %.

In which sector is Bonus Biogroup located?

Bonus Biogroup is assigned to the 'Health' sector.

Wann musste ich die Aktien von Bonus Biogroup kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Bonus Biogroup from 12/4/2024 amounting to 0 ILS, you needed to have the stock in your portfolio before the ex-date on 12/4/2024.

When did Bonus Biogroup pay the last dividend?

The last dividend was paid out on 12/4/2024.

What was the dividend of Bonus Biogroup in the year 2023?

In the year 2023, Bonus Biogroup distributed 0 ILS as dividends.

In which currency does Bonus Biogroup pay out the dividend?

The dividends of Bonus Biogroup are distributed in ILS.